

TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) – December 28, 2015, 20:00h CET – TiGenix NV (Euronext Brussels: TIG) publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

1. Summary of the notification

It concerns a notification dated December 21, 2015 by Genetrix S.L., following the transfer of shares and the downward crossing below the 3% threshold on December 18, 2015, after which the participation of Genetrix S.L. has dropped to 0 shares/voting rights (0%).

2. Content of the notification

Date of the notification: December 21, 2015.

Reason of the notification: transfer of shares and downward crossing of the lowest threshold.

Person subject to the notification requirement: Genetrix S.L., Calle Velázquez nº 24, 4º derecha, 28001 Madrid, Spain, who notifies alone.

Date on which the threshold was crossed: December 18, 2015.

Threshold that was crossed: Genetrix S.L. crossed below the 3% threshold, the lowest threshold provided by TiGenix' articles of association.

Denominator: 177,304,587.

Details of the notification: prior to the transfer of shares, Genetrix S.L. held 7,712,757 shares/voting rights; following the transfer of shares, Genetrix S.L. held 0 shares/voting rights (0%).

Chain of controlled undertakings through which the holdings are effectively held: Genetrix S.L. is not controlled.

Additional information: Genetrix S.L. transferred its TiGenix shares to its shareholders by way of distribution in kind (“*uitkering in natura*”). The Genetrix S.L. shareholders who received TiGenix shares agreed to be bound by the remainder of the lock-up provisions that applied to Genetrix SL pursuant to the Contribution Agreement entered into between TiGenix NV and Genetrix SL on 29 July 2015.

This press release and the transparency notification can be consulted on our website (press release: <http://www.tigenix.com/en/pages/11/2015>; notification: <http://www.tigenix.com/en/page/26/shareholders>).



For more information:

Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).